Immunomodulatory Activity of Mesenchymal Stem Cells
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells (MSCs) were discovered as a rare population of non-hematopoietic stem cells that reside in the bone marrow and interact closely with hematopoietic stem cells to support their growth and differentiation. MSCs are multipotent cells that have the ability to differentiate into cells of the mesenchymal lineage including adipocytes, osteocytes and chondrocytes and they have been reported to home to areas of tissue injury and participate in tissue repair. More recently, MSCs have also been described to possess anti-inflammatory and immunomodulatory properties that can affect multiple arms of the immune system. MSCs have been shown to inhibit T and B cell proliferation, downregulate the lytic activity of cytotoxic T lymphocytes and NK cells, inhibit the maturation and antigen-presenting function of dendritic cells and modulate macrophage function through both contact-dependent and contact-independent mechanisms. The administration of MSCs in models of autoimmune disease such as collagen-induced arthritis, EAE and autoimmune diabetes has provided additional evidence for an immunoregulatory role of MSCs supporting their use in controlling autoimmunity. The administration of allogeneic MSCs as immunosuppressive agents represents a viable approach as they appear to be largely non-immunogenic and clinical trials with allogeneic MSCs are currently underway in graftversus- host disease, Crohn's disease and type I diabetes indications. The immunomodulatory properties, mechanism of action and potential clinical utility of MSCs are reviewed herein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Németh, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364 · cited 2×
“This in vitro antiinflammatory activity of MSCs translated into a benefit in models of bleomycin- or LPS-induced pulmonary inflammation [77, 78] and against sepsis induced by cecal ligation and puncture [79].”
BackgroundRen, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101 · cited 2×
“Their involvement is supported by significant reversal of T cell inhibition upon suppression of PGE2 synthesis by indomethacin [43, 47, 50], inhibition of NO production by INOS inhibitors [56], or neutralization of IDO activity through silencing of the IDO gene, addition of the antagonist 1methyl L-tryptophan, or repl…”
BackgroundHuman mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis
Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., Sudo, K., & Iwakura, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.566 · Cited by 1,536
Isolation of Mesenchymal Stem Cells of Fetal or Maternal Origin from Human Placenta
in 't Anker, P. S., Scherjon, S. A., Kleijburg‐van der Keur, C., de Groot‐Swings, G. M. J. S., Claas, F. H. J., Fibbe, W. E., & Kanhai, H. H. H. (2004) · STEM CELLS · doi:10.1634/stemcells.2004-0058 · Cited by 1,189 · cited 1×
“In addition to bone marrow, MSCs are found in many adult tissues including skin, adipose tissue, heart and spleen [3-7] and in fetal tissues such as placenta, cord blood, fetal liver and lung [8-10].”
BackgroundComparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow
De Ugarte, D. A., Morizono, K., Elbarbary, A., Alfonso, Z., Zuk, P. A., Zhu, M., Dragoo, J. L., Ashjian, P., Thomas, B., Benhaim, P., et al. (2003) · Cells Tissues Organs · doi:10.1159/000071150 · Cited by 1,173 · cited 1×
“In addition to bone marrow, MSCs are found in many adult tissues including skin, adipose tissue, heart and spleen [3-7] and in fetal tissues such as placenta, cord blood, fetal liver and lung [8-10].”
BackgroundOrtiz, L. A., DuTreil, M., Fattman, C., Pandey, A. C., Torres, G., Go, K., & Phinney, D. G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704421104 · Cited by 1,019
Gold, R. (2006) · Brain · doi:10.1093/brain/awl075 · Cited by 1,017 · cited 1×
“Many EAE models exist [117] and the ones used to test the potential of MSC therapy include the chronic-progressive and relapsing/remitting models where disease is induced in C57BL/6 or SLJ mice by injection of myelin oligodendrocyte glycoprotein (MOG) or proteolipid protein (PLP) antigens, respectively.”
BackgroundInteractions Between Human Mesenchymal Stem Cells and Natural Killer Cells
Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006) · Stem Cells · doi:10.1634/stemcells.2004-0359 · Cited by 956 · cited 7×
“However, upon activation, NK cells are in fact capable of lysing MSCs [90, 91].”
BackgroundInfluentialMesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophages
Kim, J., & Hematti, P. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.09.004 · Cited by 785
Honczarenko, M., Le, Y., Swierkowski, M., Ghiran, I., Glodek, A. M., & Silberstein, L. E. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0319 · Cited by 722
Species Variation in the Mechanisms of Mesenchymal Stem Cell-Mediated Immunosuppression
Ren, G., Su, J., Zhang, L., Zhao, X., Ling, W., L'huillie, A., Zhang, J., Lu, Y., Roberts, A. I., Ji, W., et al. (2009) · Stem Cells · doi:10.1002/stem.118 · Cited by 597
Izikson, L., Klein, R. S., Charo, I. F., Weiner, H. L., & Luster, A. D. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1075 · Cited by 584 · cited 1×
“The CCL2/CCR2 pathway has been shown to play an important role in EAE development [127-130] and MSCs are known to produce CCL2 [15], suggesting that MSC-derived CCL2 might contribute to immunoregulation by these cells.”
BackgroundPlasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals
Cassese, G., Arce, S., Hauser, A. E., Lehnert, K., Moewes, B., Mostarac, M., Muehlinghaus, G., Szyska, M., Radbruch, A., & Manz, R. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.1684 · Cited by 487 · cited 1×
“MSC production of Th2-type cytokines (IL-6, IL-10) [86, 87], which are known to promote B cell proliferation and differentiation as well as plasma cell survival [88], may contribute to the stimulatory effect of MSCs although cell to cell contact has also been reported to be involved [86, 87].”
Background
Cited by
Inflammation, fracture and bone repair
Loi, F., Córdova, L. A., Pajarinen, J., Lin, T.-H., Yao, Z., & Goodman, S. B. (2016) · Bone · doi:10.1016/j.bone.2016.02.020 · Cited by 1,293
How mesenchymal stem cells interact with tissue immune responses
Shi, Y., Su, J., Roberts, A. I., Shou, P., Rabson, A. B., & Ren, G. (2012) · Trends in Immunology · doi:10.1016/j.it.2011.11.004 · Cited by 633
Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Mohyeddin Bonab, M., Ali Sahraian, M., Aghsaie, A., Ahmadi Karvigh, S., Massoud Hosseinian, S., Nikbin, B., Lotfi, J., Khorramnia, S., Reza Motamed, M., Togha, M., et al. (2012) · Current Stem Cell Research & Therapy · doi:10.2174/157488812804484648 · Cited by 176
“Modulatory effects on both adaptive and innate immunity [10, 18-20], ameliorating neural damage through paracrine secretions into neural microenvironments [5, 21] or promo-”
BackgroundLv, Y.-T., Zhang, Y., Liu, M., Qiuwaxi, J.-N.-T., Ashwood, P., Cho, S. C., Huan, Y., Ge, R.-C., Chen, X.-W., Wang, Z.-J., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-196 · Cited by 174
“MSCs have profound immunoregulatory properties and are currently being investigated as a novel cellular immunomodulatory and anti-inflammatory agent in numerous clinical trials [30].”
BackgroundFouraschen, S. M. G., Pan, Q., de Ruiter, P. E., Farid, W. R. R., Kazemier, G., Kwekkeboom, J., Ijzermans, J. N. M., Metselaar, H. J., Tilanus, H. W., de Jonge, J., et al. (2012) · Stem Cells and Development · doi:10.1089/scd.2011.0560 · Cited by 102
“MSC have the ability to differentiate into hepatocytes and cholangiocytes and have immunomodulatory and antiinflammatory properties [17–21].”
Metadata
- Authors
- M. Kaplan, J., E. Youd, M., & A. Lodie, T.
- Venue
- Current Stem Cell Research & Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-12-01
- Volume
- 6
- Issue
- 4
- Pages
- 297-316
- ISSN
- 1574-888X (ISSN-L)
- OpenAlex
- W2138056715
- Cited by
- 84
- References
- 17
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.